Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Norovirus Clear all

Conditions: Norovirus Acute Gastroenteritis
Interventions: mRNA-1403, mRNA-1405, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions: Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid; Drug
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Primary Progressive Multiple Sclerosis
Interventions: FTY720, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 33
States / cities: Newport Beach, California • Sacramento, California • Aurora, Colorado + 29 more

Conditions: Diabetes
Interventions: insulin regular IV infusion, IV insulin infusion; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Uterine Cancer
Interventions: Olaparib, Carboplatin, Paclitaxel; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 5
States / cities: Edmonds, Washington • Issaquah, Washington • Seattle, Washington

Conditions: Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
Interventions: Norovirus -specific T-cell (NST) therapy; Biological
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Months to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland

Conditions: Norovirus, Healthy Participants
Interventions: NoV GI.1/GII.4 Bivalent VLP Vaccine; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Long COVID
Interventions: RNA Biomarker Blood Test; Diagnostic Test
Lead sponsor: MaxWell Clinic, PLC; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Iowa City, Iowa • Brentwood, Tennessee

Conditions: Healthy Volunteers, Norovirus
Interventions: NoV Vaccine; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 9
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more

Conditions: Healthy
Interventions: High Hydrostatic Pressure Processing; Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Norovirus Infections
Interventions: VXA-G1.1-NN, Placebo Tablets, Norovirus GI.1 Norwalk Virus Inoculum; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Gastroenteritis Norovirus
Interventions: Norovirus GII.4 Challenge Pool CIN-1, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Adults
Interventions: Norovirus; Biological
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 49 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Neoplasms
Interventions: MK-0482, pembrolizumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Detroit, Michigan • Hackensack, New Jersey • San Antonio, Texas

Conditions: Intravenous Fluids, Fluid and Electrolyte Imbalance, ADH Inappropriate
Interventions: Education, clinical decision support tools; Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 28 Days to 18 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 89
States / cities: Phoenix, Arizona • Fresno, California • Loma Linda, California + 76 more

Conditions: Norovirus Infection
Interventions: VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gastroenteritis Norovirus
Interventions: Norovirus GII.2 Challenge, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Breast Cancer
Interventions: Neratinib, Trastuzumab, Paclitaxel; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 36
States / cities: Oxnard, California • Santa Rosa, California • Plainville, Connecticut + 32 more

Conditions: Norovirus
Interventions: CDI-988, Placebo, Snow Mountain Virus; Drug · Other
Lead sponsor: Cocrystal Pharma, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Gulf War Illness
Interventions: Draw blood (phlebotomy, 83 ml); Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Norovirus Infections
Interventions: VXA-G1.1-NN; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Norovirus Gastroenteritis
Interventions: VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Safety tested norovirus inoculum; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Norovirus Prevention
Interventions: Norovirus Bivalent VLP Vaccine, Placebo (Saline); Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more

Search by objective public record fields.

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

Comparison of the Leuven Protocol With the Glucommander for Postoperative Control of Blood Glucose With IV Insulin

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

Infectivity of Norovirus in Shellfish Treated With High Hydrostatic Pressure Processing-Human Challenge Study

Norovirus Challenge Study

Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

Susceptibility of Human Volunteers With Different Histo-Blood With Different Histo-Blood Group Antigens to Norovirus

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus

"Immunomodulation in GWI (Phlebotomy)"

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Infectivity of Norovirus in Groundwater-Human Challenge Study

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults